Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis: The ACCESS Randomized Trial

• Autores: Steven M. Opal, Pierre-Francois Laterre, François Bruno, Steven P. LaRosa, Derek C. Angus
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 309, Nº. 11, 2013, págs. 1154-1162
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response.